Harbin Gloria Pharmaceuticals Co., Ltd (002437.SZ)
CNY 2.36
(-1.26%)
CNY 2.36
(-1.26%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -36.41 Million CNY | -116.76% |
| 2022 | 217.23 Million CNY | 248.04% |
| 2021 | 62.41 Million CNY | -86.34% |
| 2020 | 456.99 Million CNY | -66.54% |
| 2019 | 1.36 Billion CNY | -24.74% |
| 2018 | 1.81 Billion CNY | -30.43% |
| 2017 | 2.6 Billion CNY | 3.59% |
| 2016 | 2.51 Billion CNY | 3.87% |
| 2015 | 2.42 Billion CNY | 2117.51% |
| 2014 | -120.16 Million CNY | 85.52% |
| 2013 | -829.92 Million CNY | 32.95% |
| 2012 | -1.23 Billion CNY | 13.05% |
| 2011 | -1.42 Billion CNY | 7.46% |
| 2010 | -1.53 Billion CNY | -38229.33% |
| 2009 | 4.03 Million CNY | -58.46% |
| 2008 | 9.71 Million CNY | 282.33% |
| 2007 | -5.32 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -275.44 Million CNY | -656.39% |
| 2024 Q2 | -318.88 Million CNY | -15.77% |
| 2024 Q3 | -425.17 Million CNY | -32.18% |
| 2023 Q3 | -135.81 Million CNY | -685.36% |
| 2023 Q4 | -36.41 Million CNY | 73.19% |
| 2023 FY | -36.41 Million CNY | -116.76% |
| 2023 Q1 | 126.54 Million CNY | -41.75% |
| 2023 Q2 | 23.2 Million CNY | -81.67% |
| 2022 Q3 | 192.26 Million CNY | -20.91% |
| 2022 FY | 217.23 Million CNY | 248.04% |
| 2022 Q4 | 217.23 Million CNY | 12.98% |
| 2022 Q2 | 243.1 Million CNY | -2.98% |
| 2022 Q1 | 250.57 Million CNY | 301.45% |
| 2021 FY | 62.41 Million CNY | -86.34% |
| 2021 Q4 | 62.41 Million CNY | -73.84% |
| 2021 Q1 | 305.15 Million CNY | -33.23% |
| 2021 Q2 | 338.81 Million CNY | 11.03% |
| 2021 Q3 | 238.59 Million CNY | -29.58% |
| 2020 Q2 | 577.45 Million CNY | 13.87% |
| 2020 Q4 | 456.99 Million CNY | -27.09% |
| 2020 FY | 456.99 Million CNY | -66.54% |
| 2020 Q1 | 507.12 Million CNY | -62.87% |
| 2020 Q3 | 626.79 Million CNY | 8.54% |
| 2019 Q1 | 1.71 Billion CNY | -5.7% |
| 2019 FY | 1.36 Billion CNY | -24.74% |
| 2019 Q4 | 1.36 Billion CNY | 6.46% |
| 2019 Q3 | 1.28 Billion CNY | -15.04% |
| 2019 Q2 | 1.51 Billion CNY | -11.77% |
| 2018 Q4 | 1.81 Billion CNY | -20.98% |
| 2018 Q3 | 2.29 Billion CNY | -8.06% |
| 2018 FY | 1.81 Billion CNY | -30.43% |
| 2018 Q1 | 2.66 Billion CNY | 2.27% |
| 2018 Q2 | 2.49 Billion CNY | -6.37% |
| 2017 Q4 | 2.6 Billion CNY | 1.22% |
| 2017 FY | 2.6 Billion CNY | 3.59% |
| 2017 Q1 | 2.59 Billion CNY | 3.2% |
| 2017 Q2 | 2.58 Billion CNY | -0.57% |
| 2017 Q3 | 2.57 Billion CNY | -0.26% |
| 2016 Q2 | 2.92 Billion CNY | 3.95% |
| 2016 Q1 | 2.81 Billion CNY | 16.09% |
| 2016 Q4 | 2.51 Billion CNY | -12.48% |
| 2016 Q3 | 2.87 Billion CNY | -1.65% |
| 2016 FY | 2.51 Billion CNY | 3.87% |
| 2015 Q1 | 2.16 Billion CNY | 1904.04% |
| 2015 FY | 2.42 Billion CNY | 2117.51% |
| 2015 Q3 | 2.04 Billion CNY | -1.76% |
| 2015 Q4 | 2.42 Billion CNY | 18.37% |
| 2015 Q2 | 2.08 Billion CNY | -3.83% |
| 2014 Q4 | -120.16 Million CNY | -191.76% |
| 2014 Q3 | 130.94 Million CNY | -46.38% |
| 2014 FY | -120.16 Million CNY | 85.52% |
| 2014 Q1 | -190.73 Million CNY | 77.02% |
| 2014 Q2 | 244.22 Million CNY | 228.05% |
| 2013 Q2 | -677.19 Million CNY | 40.49% |
| 2013 Q4 | -829.92 Million CNY | -12.99% |
| 2013 FY | -829.92 Million CNY | 32.95% |
| 2013 Q1 | -1.13 Billion CNY | 8.06% |
| 2013 Q3 | -734.48 Million CNY | -8.46% |
| 2012 Q4 | -1.23 Billion CNY | 4.52% |
| 2012 FY | -1.23 Billion CNY | 13.05% |
| 2012 Q3 | -1.29 Billion CNY | -3.36% |
| 2012 Q2 | -1.25 Billion CNY | 12.43% |
| 2012 Q1 | -1.43 Billion CNY | -0.61% |
| 2011 Q3 | -1.38 Billion CNY | 4.2% |
| 2011 Q1 | -1.45 Billion CNY | 5.49% |
| 2011 Q4 | -1.42 Billion CNY | -2.45% |
| 2011 FY | -1.42 Billion CNY | 7.46% |
| 2011 Q2 | -1.45 Billion CNY | 0.24% |
| 2010 Q2 | -1.69 Billion CNY | -6591.95% |
| 2010 Q3 | -1.52 Billion CNY | 9.77% |
| 2010 Q4 | -1.53 Billion CNY | -0.73% |
| 2010 FY | -1.53 Billion CNY | -38229.33% |
| 2010 Q1 | 26.06 Million CNY | 546.17% |
| 2009 Q4 | 4.03 Million CNY | 0.0% |
| 2009 FY | 4.03 Million CNY | -58.46% |
| 2008 FY | 9.71 Million CNY | 282.33% |
| 2007 FY | -5.32 Million CNY | 0.0% |